Kenneth Hoberman insider trades

Open-market stock purchases and sales by Kenneth Hoberman, Director at Nuvectis Pharma, Inc, from SEC Form 4 filings since Dec 16, 2009.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -45%.

Recent trades

DateStockTradeValue
Jun 11, 2026NVCT Nuvectis Pharma, IncBought (not open market)—
Jun 11, 2026TGTX TG Therapeutics, IncBought (not open market)—

Companies traded

  • NVCT Nuvectis Pharma, Inc: 1 buy, last Jun 11, 2026
  • TGTX TG Therapeutics, Inc: other filings, last Jun 11, 2026
  • STML Stemline Therapeutics Inc: 1 buy, 38 sales, last Jun 10, 2020

Get free alerts when Kenneth Hoberman files a new trade →